唐配方通过AMPK/PGC-1α/MFN2通路激活来缓解糖尿病坐骨神经病变
Cunqing Yang1, Honghai Yu2,3, Linfeng Zhou4
1Guang'anmen Hospital Affiliated to China Academy of Chinese Medical Sciences , Beijing, China.
Scientific reports
|July 11, 2025
概括
唐配方 (TBF) 通过保护神经和改善线粒体功能,有效治疗糖尿病外围神经病变 (DPN). 这项研究阐明了TBF的机制,表明它激活AMPK-PGC-1α-MFN2通路以促进神经再生和减少DPN症状.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 生物化学 生物化学
背景情况:
- 糖尿病外围神经病变 (DPN) 是一种常见的,使人虚弱的糖尿病并发症,影响神经系统.
- 唐二配方 (TBF) 显示了对DPN的治疗前景,但其精确的神经保护机制需要阐明.
- 了解TBF的机制对于开发针对DPN的向治疗至关重要.
研究的目的:
- 用动物和细胞模型澄清Tang Bi配方 (TBF) 在糖尿病外围神经病变 (DPN) 中的神经保护机制.
- 通过UHPLC/QTOF-MS和网络药理学来识别TBF的生物活性成分和潜在的治疗点.
- 评估TBF在改善DPN相关的神经损伤和功能障碍方面的疗效.
主要方法:
- 在老鼠和施万细胞 (SCs) 中建立了DPN模型.
- 利用UHPLC/QTOF-MS和网络药理学来识别TBF的活性化合物和标.
- 评估了TBF对神经功能,组织学,细胞活力,细胞亡,线粒体潜力,ROS水平和关键通路蛋白质表达 (AMPK-PGC-1α-MFN2) 的影响.
主要成果:
- 在TBF中确定了11个生物活性成分.
- 在DPN大鼠中,TBF治疗改善了神经传导速度,降低了疼痛过敏,促进了髓膜再生,增强了神经纤维密度.
- 在体外,TBF保护了SCs免受高葡萄糖诱导的亡,减少了氧化应激和线粒体功能障碍,并激活了AMPK-PGC-1α-MFN2通路.
结论:
- 唐双配方 (TBF) 显示出糖尿病外围神经病变 (DPN) 的显著治疗潜力.
- 通过纠正线粒体动态失衡和激活AMPK-PGC-1α-MFN2通路,TBF具有神经保护作用.
- 这些作用促进神经发生和缓解外围神经损伤,支持TBF作为DPN的可行的治疗方法.
关键词:
1α1α是指1α1α1α1α1α1α1α1α1α1α1α1α1α1α1α糖尿病外围神经病变,UHPLC/QTOF 的研究结果MFN2通路,线粒体动力学,施万细胞在MS,AMPKK.在PGC中,PGC是PGC.更多相关视频
08:20Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain
Published on: June 30, 2023
2.1K
08:16Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
6.6K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Glucagon-like Receptor Agonists
424
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
424
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
